Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck
April 16, 2018 14:10 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced data from its ongoing Phase 1b/2 study investigating SD-101, Dynavax's...
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
April 03, 2018 16:30 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on March 29, 2018 the Compensation Committee of Dynavax’s Board of Directors...
Dynavax Announces Acceptance of Two Data Abstracts for SD-101 in Combination with KEYTRUDA® for Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting
March 15, 2018 06:30 ET
|
Dynavax Technologies Corporation
Data from Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Durability Data in Advanced Metastatic Melanoma BERKELEY, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Dynavax...
Dynavax Reports Fourth Quarter and Year End 2017 Financial Results
March 08, 2018 06:30 ET
|
Dynavax Technologies Corporation
HEPLISAV-B Launched in the United States Phase 2 Data in Two Immuno-oncology Programs Planned for First Half 2018 BERKELEY, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies...
Dynavax to Present at the Cowen & Co. Annual Health Care Conference
March 05, 2018 16:30 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that Eddie Gray, Dynavax’s Chief Executive Officer, will present at the Cowen...
Stanley A. Plotkin, M.D. Steps Down from Board of Dynavax Technologies
March 02, 2018 06:30 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif., March 02, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (“Dynavax”) (NASDAQ:DVAX) announced today that Stanley A. Plotkin, M.D. has indicated his intention to step down...
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
March 01, 2018 16:45 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on March 1, 2018 the Compensation Committee of Dynavax’s Board of Directors...
Dynavax’s HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults
February 21, 2018 09:36 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on...
Dynavax Secures $175 Million in Non-Dilutive Debt Financing
February 20, 2018 06:30 ET
|
Dynavax Technologies Corporation
Proceeds to be Used to Commercialize HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] in United States and Advance Company’s Immuno-Oncology Product Candidates Company Deploying HEPLISAV-B...
Dynavax to Present at the RBC Capital Markets Global Healthcare Conference
February 14, 2018 08:00 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that Eddie Gray, Dynavax’s chief executive officer, will participate in a fireside...